Evofem Biosciences, Inc.
EVFM · OTCMCIK 1618835fmd_0E4CSPX34A15QBWXNVPJZ2HHD1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 8 | 17 | 18 | 19 | 20 |
| Cost of revenue | – | – | – | 0 | 0 | 4 | 4 | 7 | 4 | 5 |
| Gross profit | – | – | – | 0 | (0) | 4 | 12 | 12 | 16 | 16 |
| Research and development | 15 | 24 | 43 | 22 | 17 | 33 | 25 | 3 | 2 | – |
| Selling, general and administrative | – | – | – | 31 | 87 | 138 | 72 | 27 | 21 | 17 |
| Total operating expenses | 35 | 36 | 78 | 53 | 104 | – | – | – | – | – |
| Operating income | (35) | (36) | (78) | (53) | (104) | (167) | (84) | (18) | (8) | 3 |
| Interest expense | 1 | – | – | 0 | 2 | 3 | 2 | 2 | 2 | 2 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (34) | (70) | (48) | (27) | (39) | (38) | 7 | 71 | (1) | (3) |
| Income before taxes | (68) | (105) | (126) | (80) | (142) | (205) | (77) | 53 | (9) | 0 |
| Income tax expense | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | 0 |
| Net income from continuing operations | (68) | (105) | (126) | (80) | (142) | (205) | (77) | 53 | – | 0 |
| Net income | (67) | (105) | (126) | (80) | (142) | (205) | (77) | 53 | (9) | 0 |
| Net income to common shareholders | (68) | (109) | (126) | (80) | (142) | (206) | (78) | 50 | (9) | 0 |